Aventis Pasteur
Uses MRC-5 in their Rabies Vaccine ; plans to use PER C6 in future products
David J. Williams, President & CEO
Aventis Pasteur
Box 187 Discovery Drive
Swiftwater, PA
18370
www.aventispasteur.com/
Pfizer Corporation
Withdrew from PER C6 license agreement
Write to thank them!
Hank McKinnell, CEO
Pfizer Corp. World Headquarters
235 E 42nd St.
New York, NY 10017
http://www.pfizer.com/main.html
Novartis
Plans on using PER C6 in future. Write to tell them not to!
Thomas Ebeling, CEO
Novartis Pharmaceuticals Corp.
One Health Plaza
East Hanover, NJ 07936-1080
http://www.novartis.com/
Glaxo SmithKline
(formerly SmithKline Beecham)
Uses MRC-5 in their Hepatitis-A and Twinrix
(Hepatitis-A-B combo) vaccines; plans on using
PER C6 in future
David Stout, President, Pharmaceuticals
Glaxo SmithKline
1 Franklin Plaza P.O. Box 7929
Philadelphia, PA
19101
http://www.gsk.com/index.htm
Schering-Plough
Plans on using PER C6 in future. Write to tell them not to!
Richard Jay Kogan, CEO
Schering-Plough
2000 Galloping Hill Rd.
Kenilworth, NJ 07033-0530
Merck & Company
Uses WI-38 and MRC-5 in their MMR, Chickenpox,
Hepatitis-A vaccines; Using PER C6
in a new HIV vaccine.
Raymond V. Gilmartin, CEO
Merck & Co.
770 Sumneytown Pike P.O. Box 4
Westpoint, PA
19486
www.merck.com
MedImmune, Inc.
Plans on using PER C6 in a new Flu Vaccine
David M. Mott, Chief Executive Officer
MedImmune, Inc.
35 W. Watkins Mill Rd.
Gaithersburg, MD 20878
National Institutes of Health
(Governed by the Dept. of HHS)
Plans on using PER C6 in new Ebola Vaccine.
The Honorable Tommy Thompson
Department of Health & Human Services
200 Independence Avenue, S.W. Room 615-F
Washington, D.C. 20201
CDC
Dr. Julie
Gerberding
Centers
for Disease Control
1600 Clifton RD NE MS D66
Atlanta, GA 30333
nipinfo@cdc.gov
www.cdc.gov
FDA
Center for Biological Evaluation & Review
Federal Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20895
WWW.fda.gov
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608-2916
Phone: (510) 655-8730
Fax: (510) 655-9910
www.chiron.com
Nabi Biopharmaceuticals
Boca Raton, Florida
Corporate Headquarters and Manufacturing Facility
5800 Park of Commerce Blvd, N.W.
Boca Raton, FL 33487
Toll: 800-635-1766
Phone: 561-989-5800
Fax: 561-989-5801
Rockville, Maryland
Research and Development Facility
12276 Wilkins Avenue
Rockville, MD 20852
Toll: 800-685-5579
Phone: 301-770-3099
Fax: 301-770-3097
email: invinf@nabi.com
www.nabi.com
Wyeth
Wyeth
5 Giralda Farms
Madison, NJ 07940
Animal Health Products: 1-800-685-5656
Investors Relations: 877-552-4744
www.wyeth.com
SINOVAC BIOTECH LTD.
No.39 Shangdi Xi Rd,
Haidian District,
Beijing,P.R. CHINA
Sinovac Biotech Ltd. specializes in the
research, development, commercialization, and sales of human vaccines for infectious
illnesses such as Hepatitis A and Hepatitis B, influenza and "SARS."
Sinovac is one of the leading emerging biotechnology companies in
China. Working closely with Chinese public health officials, Sinovac focuses on
manufacturing and marketing human-use vaccines and related products, and currently
markets its vaccine for Hepatitis A. Sinovac is the first and currently the only
company in the world to have been granted permission to begin clinical trials for a
vaccine to prevent SARS.
Investor Relations at (888) 888 8312 or (604) 684-5990 or info@sinovac.com .
www.sinovac.com.
Cambrex Biopharmaceuticals
Services
Baltimore Facility
Cambrex Bio Science Baltimore Inc.
5901 E. Lombard Street
Baltimore, MD 21224
Hopkinton Facility
Cambrex Bio Science Hopkinton Inc.
97 South Street
Hopkinton, MA 01748
Cambrex Biopharmaceutical Manufacturing
Services
Tel : 877-676-5888
Fax : 410-563-9206
biopharmainfo@cambrex.com
http://www.cambrex.com/content/biopharm/biopharm.asp
